*Temporary enrollment pause due to coronavirus (COVID-19)*

Please note that study site locations for this study may not be accepting new study participants at this time in light of the situation with the coronavirus (COVID-19). Please check back at a later date as we expect to continue recruitment/enrollment in the future as this situation changes.

Who is eligible to participate?

The COMMANDS Trial may be an option for those who meet the following criteria:
• Are 18 years of age and older
• Have been diagnosed with MDS with anemia
• Require blood cell transfusions

If you meet these initial criteria, we invite you to take the prescreening questionnaire to see if you may qualify to participate in this study.

More about COMMANDS trial participation

Participation in the study lasts approximately six years (and may be shorter or longer for certain patients). This includes:

• a screening period of approximately 35 days,
• an initial 24-week treatment period (which may be extended if certain criteria are met and if you continue to benefit from the treatment), and
• a follow-up period where you will be contacted approximately every 12 weeks to ask how you are doing. 

The study drug being used in the COMMANDS Trial is called luspatercept, which is a protein that aims to help increase the production of red blood cells in bone marrow. Luspatercept will be administered as an injection every three weeks during the treatment period.